EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today provided an update on new clinical developments and other initiatives related to Ceplene® (histamine dihydrochloride), the Company’s therapy approved in the European Union for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.
EpiCept announced plans to initiate two new studies for Ceplene and provided an update on another study for Ceplene intended to help achieve an expanded indication and broaden use for the drug.
Read full story at
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20091214006392&newsLang=en
No comments:
Post a Comment